1. Australia Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sigma Healthcare Ltd

Sigma Healthcare Ltd

1.74
EUR
0.00
(0.00%)
0.04EPS
Mar 04Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2025 Y
2026 Y
Revenue per Share
2.96
3.4
4.32
4.08
4.05
3.28
3.41
3.45
3.59
3.3
3.09
0.57
0.94
Basic EPS, GAAP
0.05
0.05
0.05
0.05
0.04
-0.01
0.06
-0.01
- -
- -
-0.01
0.05
0.06
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.02
0.05
0.05
0.05
0.04
0.03
- -
0.02
0.02
0.01
0.01
0.11
0.03
Book Value per Share
0.51
0.5
0.48
0.47
0.47
0.44
0.49
0.45
0.44
0.53
0.51
0.41
0.43
Tangible Book Value per Share
0.42
0.41
0.39
0.35
0.36
0.31
0.34
0.33
0.33
0.47
0.45
0.07
0.1
Basic Weighted Avg Shares
1,073
1,033
1,023
1,013
995
1,005
1,017
1,019
1,021
1,024
1,572
10,478
11,502
Sales/Revenue/Turnover
3,179
3,515
4,421
4,130
4,029
3,299
3,467
3,516
3,660
3,376
4,852
6,002
10,835
Operating Margin (%)
1.97
1.94
1.58
0.01
0.4
-1.41
-0.25
-1.16
-2.06
-0.54
-1.07
11.11
8.37
Depreciation Expense
8
10
8
9
14
27
31
28
30
28
26
56
85
Net Income, GAAP
53
51
53
55
37
-12
60
-7
2
5
-14
530
709
Effective Tax Rate (%)
30.19
34.36
30.21
29.66
28.71
- -
- -
- -
44.58
38.42
215.9
29.33
29.49
Profit Margin (%)
1.66
1.44
1.2
1.33
0.91
-0.37
1.72
-0.21
0.05
0.13
-0.29
8.83
6.55
Working Capital
402
380
344
249
341
160
179
304
208
541
512
1,206
1,376
LT Debt
- -
1
1
1
201
157
140
298
214
127
121
1,877
1,813
Total Equity
573
554
539
515
514
477
535
489
478
873
839
4,661
4,990
Return on Invested Capital (%)
7.51
7.28
8.01
0.07
1.57
- -
- -
- -
-6.02
-1.31
6.05
12.04
9.02
Return on Capital (%)
9.64
9.02
9.51
9.24
5.77
- -
- -
- -
1.13
1.6
-3.66
14.48
10.81
Return on Common Equity (%)
9.16
8.98
9.77
10.49
7.12
-2.49
11.83
-1.42
0.38
0.67
-1.62
19.24
14.67

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
53.07%
107.79%
7.06%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-513.82%
-855.5%
33.83%
Sales/Revenue/Turnover
12.37%
28.86%
80.53%
Total Cash Common Dividend
776.88%
1,352.27%
-68.06%

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
6,002
2026
- -
- -
10,835

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
0.05
2026
- -
- -
0.06

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
0.11
2026
- -
- -
0.03

Company Description

Company Profile APIChatGPT
CEO
Vikesh Ramsunder
Full Time Employees
156
Sector
Health technology
Industry
Pharmaceuticals: major
Address
6 Albert Street Clayton VIC Australia 3072
IPO Date
Oct 30, 2002
Website
sigmahealthcare.com.au
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sigma Healthcare Limited (ASX:SIG), founded in 1912 and headquartered in Clayton, Australia, is Australia's largest full-line pharmaceutical wholesaler and retail pharmacy franchisor, supplying prescription medicines, over-the-counter products, front-of-store goods, medical consumables and fast-moving consumer goods to more than 3,500 pharmacies nationwide through its extensive distribution network; it operates prominent retail brands including Chemist Warehouse, Amcal, Discount Drug Stores and PriceSave, alongside the Ultra Beauty retail beauty offering, while providing third-party logistics (3PL) solutions, electronic medication management systems such as MPS MediSphere and PharmacyiQ online training, and end-to-end medication management connecting general practitioners to community and aged care facilities. The company serves franchised and independent pharmacies, hospitals and consumers across Australia, with international operations in New Zealand, Ireland, China and Dubai. In February 2025, Sigma completed its transformational merger with Chemist Warehouse Group, under which Chemist Warehouse shareholders hold approximately 85.75% of the enlarged entity, enabling accelerated growth through complementary strengths in distribution, franchising and omnichannel retailing; the merged group reported strong first-half financial results in August 2025, including 35% EBIT growth, margin expansion and new store openings including in Dubai, while launching initiatives such as a new PharmacyiQ learning portal, a Tasmanian distribution centre and expanded private label ranges.